Evidence map›Paper›PMID 39001495›Full record

ReviewCancers2024

Role of Lutetium Radioligand Therapy in Prostate Cancer.

Ignacy Książek, Artur Ligęza, Franciszek Drzymała, Adam Borek, Marcin Miszczyk, Marcin Radosław Francuz, Akihiro Matsukawa, Takafumi Yanagisawa, Tamás Fazekas, Łukasz Zapała and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ignacy KsiążekDepartment of Urology, Medical University of Silesia, 41-800 Zabrze, Poland.
Artur LigęzaDepartment of Urology, Medical University of Silesia, 41-800 Zabrze, Poland.
Franciszek DrzymałaDepartment of Urology, Medical University of Silesia, 41-800 Zabrze, Poland.
Adam BorekDepartment of Urology, Medical University of Silesia, 41-800 Zabrze, Poland.
Marcin MiszczykDepartment of Urology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-4375-0827
Marcin Radosław FrancuzDepartment of Urology, Medical University of Silesia, 41-800 Zabrze, Poland.
Akihiro MatsukawaDepartment of Urology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-3324-762X
Takafumi YanagisawaDepartment of Urology, Jikei University School of Medicine, Tokyo 105-8461, Japan.ORCID 0000-0002-7410-0712
Tamás FazekasDepartment of Urology, Semmelweis University, 1085 Budapest, Hungary.
Łukasz ZapałaClinic of General, Oncological and Functional Urology, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0001-7340-280X
Paweł RajwaDepartment of Urology, Medical University of Silesia, 41-800 Zabrze, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Theranostics utilize ligands that chelate radionuclides and selectively bind with cancer-specific membrane antigens. In the case of prostate cancer (PCa), the state-of-the-art lutetium-177-PSMA combines the radioactive β-emitter

Indexed as

Lutetium-177-PSMAprostate cancerradiation therapyradioactive isotopes

Identifiers

PMID39001495
PMCPMC11240688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.